These results suggest that the combination of IL-12/IL-18-pretreated NK cells with sorafenib can not only directly inhibit tumor cells but also modulate the tumor microenvironment, ultimately leading to more favorable treatment outcomes. Here, IL18 is linked to neoplasm.